NCT02204085View on ClinicalTrials.gov

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid Leukemia, in RelapseRecurrent Adult Acute Myeloid Leukemia
Interventions
DRUG

GO-203-2c

DRUG

GO-203-2c + Decitabine

Trial Locations (2)

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT02204085 - A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter